Latest Breaking News On - Proliferation inducing ligand - Page 2 : comparemela.com

SanReno Therapeutics Announces Acquisition by Novartis in Pivotal Transaction to Bring Forward Transformative Therapeutics in Kidney Disease

/PRNewswire/ SanReno Therapeutics, a clinical-stage company specializing in the discovery, development, and commercialization of innovative therapies for.

Haoyu huangFrazier life sciencesGreater chinaReno therapeuticsVenture partners chinaSamsara biocapitalVersant venturesChinook therapeuticsProliferation inducing ligandChief executive officer

Sanreno Therapeutics Announces Acquisition By Novartis In Pivotal Transaction To Bring Forward Transformative Therapeutics In Kidney Disease

Sanreno Therapeutics Announces Acquisition By Novartis In Pivotal Transaction To Bring Forward Transformative Therapeutics In Kidney Disease
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Haoyu huangFrazier life sciencesGreater chinaReno therapeuticsVenture partners chinaSamsara biocapitalVersant venturesChinook therapeuticsProliferation inducing ligandChief executive officer

Aurinia Submits IND Application to US Food & Drug Administration for AUR 200

AUR200, a potent recombinant fusion protein, has a clinically validated MOA with a high affinity for targeting both BAFF and APRIL Upon FDA clearance of the IND, AUR 200 will be studied in a.

United statesVolker knappertzResearch developmentDrug administrationAmerican college of rheumatology convergenceAurinia pharmaceuticalsAurinia pharmaceuticals incInvestigational new drugB cell activating factorProliferation inducing ligandExecutive vice presidentAmerican collegeRheumatology convergenceIncreased potencyAccessed december

Aurinia Pharmaceuticals Inc Submits IND Application to US Food & Drug Administration for AUR 200

Aurinia Pharmaceuticals Inc. announced the submission of its Investigational New Drug application to the U.S. Food and Drug Administration for AUR200, a potential next generation therapy for B-cell.

Drug administrationAurinia pharmaceuticals incAmerican college of rheumatology convergenceAurinia pharmaceuticalsInvestigational new drugB cell activating factorProliferation inducing ligandAmerican collegeRheumatology convergence

Aurinia Pharmaceuticals (AUPH) Submits IND Application to the FDA for AUR 200

Aurinia Pharmaceuticals (AUPH) Submits IND Application to the FDA for AUR 200
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Volker knappertzAmerican college of rheumatology convergenceAurinia pharmaceuticals incResearch developmentDrug administrationAurinia pharmaceuticalsInvestigational new drugB cell activating factorProliferation inducing ligandExecutive vice presidentAmerican collegeRheumatology convergence